Literature DB >> 3258361

Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans.

S A Rosenberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3258361     DOI： 10.1200/JCO.1988.6.3.403

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

Review 1.  Gene therapy for urologic cancer.

Authors:  Fernando A Ferrer; Ronald Rodriguez
Journal:  Curr Urol Rep       Date:  2002-02       Impact factor: 3.092

2.  Is human cell therapy research caught in a mousetrap?

Authors:  A John Barrett; J Joseph Melenhorst
Journal:  Mol Ther       Date:  2011-02       Impact factor: 11.454

Review 3.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

4.  Immunotherapy of glioblastoma with intratumoural administration of autologous lymphocytes and human lymphoblastoid interferon. A further clinical study.

Authors:  J Vaquero; R Martínez; J Ramiro; F G Salazar; L Barbolla; C Regidor
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

Review 5.  Lymphokine activated killer cells.

Authors:  A Lindemann; F Herrmann; W Oster; R Mertelsmann
Journal:  Blut       Date:  1989-10

Review 6.  Hepatic artery infusion and chemoembolization in the management of liver metastases.

Authors:  S Wallace; C H Carrasco; C Charnsangavej; W R Richli; K Wright; C Gianturco
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

7.  Influence of various cytokines on the interleukin-2-dependent lysis of melanoma cells in vitro.

Authors:  E S Schultz; R Dummer; J C Becker; D Zillikens; G Burg
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

8.  Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases.

Authors:  K Okuno; H Ohnishi; I Nakajima; Y Akabane; K Kurooka; K Koh; K Shindo; M Yasutomi
Journal:  Surg Today       Date:  1994       Impact factor: 2.549
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.